350 results about "Controlled drugs" patented technology

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

The invention discloses an intelligent detection method for medicine components and medicine quality, and belongs to the field of artificial intelligence. The method comprises the following steps: acquiring a drug sample solution and a control drug solution, and injecting the drug sample solution and the control drug solution into a high performance liquid chromatography system; determining whether operation parameters of the high performance liquid chromatography system need to be adjusted or not; determining operation parameter adjustment information, and continuously updating operation parameters of the high performance liquid chromatography analysis system until a complete drug sample chromatogram and a complete control drug chromatogram are obtained; determining medicine component information and impurity component information of the sample medicine; and determining whether the sample medicine reaches a preset medicine quality evaluation standard or not according to the medicine component information and the impurity component information, and if the preset medicine quality evaluation standard is reached, determining that the sample medicine passes quality detection. According to the scheme, the manual operation time and personal errors can be reduced, the detection efficiency and accuracy are improved, and the analysis result is more accurate and stable.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

A three-dimensional scaffold for use in engineered tissue includes a repeated 3D geometry; and at least one of a hydrogel, a biocompatible polymer, and a bioprintable polymer. The repeated 3D geometry may include an open geometry including a plurality of interconnected nodes configured to be seeded with living cells. The scaffold may be formed via bioprinting. The three-dimensional scaffold may also be used for (1) 3D tissue modelling (for liver, kidney, gut, pancreas, heart, lung, spleen, etc.), (2) disease modeling of different tumor types such as breast, colorectal, lung, liver, brain, ovarian and others, (3) drug testing / therapeutic screening of small molecule drugs, peptides, proteins, antibodies, ADCs, gene therapies, RNA-based therapeutics, cell therapies, and tissue therapies, and (4) therapeutic / drug delivery (i.e., via delivery device that can be used to control drug release based on different patterns).

The present invention relates to a natural light crosslinked hydrogel comprising MXene and a method for preparing same. The present invention provides a natural polymeric hydrogel formed through natural light crosslinking in a non-harmful visible light spectrum. As the hydrogel comprises a drug and MXene, the hydrogel exhibits excellent biocompatibility with no cytotoxicity. It has been confirmed that the hydrogel can maximize a wound healing effect by modulating photothermal reactions and controlling drug release. Accordingly, the hydrogel may be effectively used for wound treatment as a pharmaceutical composition, a quasi-drug composition, and a cosmetic composition.

An emulsion comprises a first discontinuous phase comprising first droplets, a second discontinuous phase comprising second droplets, and a continuous aqueous phase. The first droplets include at least one first surfactant and at least one first fluorocarbon, and have a first diameter of more than 100 nm. The second droplets include at least one surfactant, at least one drug, and at least one solvent, and have a second diameter of no more than 100 nm.

The invention relates to the field of biological medicine, in particular to IMSFs hydrogel, a ferroptosis induction system, a preparation method and application. The IMSFs hydrogel comprises a hydrogel body, and ferroferric oxide nanoparticles and sorafenib are loaded in the hydrogel body in a wrapping manner. The IMSFs hydrogel can be used as an injectable cascade ferroptosis anti-cancer drug. The preparation method of the IMSFs hydrogel comprises the following steps: firstly, preparing a silk fibroin-hyaluronic acid hydrogel body: dissolving silk hydrogel and hyaluronic acid in a lithium bromide solution; bDDE is added into the dissolved solution, and incubation is carried out; then dialyzing and washing with deionized water to obtain a silk fibroin-hyaluronic acid hydrogel body; and then loading the sorafenib nanoparticles and the ferroferric oxide nanoparticles into the silk fibroin-hyaluronic acid hydrogel body. The IMSFs hydrogel disclosed by the invention integrates magnetic thermal response and drug controlled release, and can be injected to a tumor site, so that the treatment effect on TNBC is remarkably improved.

Described herein are compositions, systems, and methods for targeted and controlled drug release. In some embodiments, the compositions, systems, and methods may comprise magnetoelectric silica nanoparticles for targeted and controlled release of chemotherapeutic drugs for cancer treatment. In some embodiments, an external magnetic field may be used to release one or more drugs from the magnetoelectric silica nanoparticles. The disclosed compositions, systems, and methods may improve drug targeting and reduce systemic drug toxicity.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

The embodiment of the invention provides breast cancer targeting nanoparticles as well as a preparation method and application thereof. According to the embodiment of the invention, the breast cancer targeting nanoparticles are synthesized by preparing the pH sensitive polymer, carrying out co-coupling modification on the pH response polymer and the folic acid albumin nano-carrier and utilizing a controlled desolvation method; the breast cancer targeting nanoparticle is combined with a nano preparation passive targeting strategy, a tumor microenvironment stimulation response strategy and a folic acid active targeting strategy, the effects of an EPR effect, PEG shedding, charge overturning, folic acid ligand-receptor combination and the like are utilized, precise targeting and specific response of tumors are achieved, and targeted accumulation of drugs in a tumor microenvironment is comprehensively improved. Therefore, the breast cancer targeting nanoparticles prepared by the embodiment have the advantages of high targeting property, drug controlled release, improvement of solubility and absorptivity of indissolvable drugs and the like, so that the curative effect of the drugs can be enhanced, the toxic and side effects can be reduced, and the breast cancer targeting nanoparticles have wide application prospects in the field of anti-tumor treatment.

The invention belongs to the technical field of nano-carriers, and particularly relates to a casein-based nano-carrier with slow release and pH / NIR dual response as well as a preparation method and application thereof, casein is combined with hollow copper sulfide nano-particles to load drugs, the nano-carrier with slow release and pH / NIR dual response is generated, and the drug loading rate is as high as 96.84%. Experiments show that the nano-carrier can accurately control drug release under specific pH and near-infrared light irradiation, so that the drug treatment efficiency is improved, and side effects on normal tissues are reduced.

The invention provides a semeglutide long-acting sustained release microsphere and a preparation method of the semeglutide long-acting sustained release microsphere. According to the method, the semeglutide long-acting sustained-release microspheres are prepared based on a water-in-oil-in-oil (W / O / O) phase separation method. According to the method, the problems of low drug loading capacity and high burst release of a water-in-oil-in-water (W1 / O / W2 type) multiple emulsion method are solved; meanwhile, the particle size of the long-acting and sustained-release microspheres of the semeglutide is between 10 microns and 300 microns, the particle size distribution Span value is between 0.5 and 1.5, and compared with a control drug, the long-acting and sustained-release microspheres of the semeglutide have no burst release effect and no drug release lagging stage after being administrated, have the same onset time as the control drug in an animal body, can be slowly released for one month and have a remarkable blood glucose reducing effect.

Embodiments of the present invention relate to mechanically-activated microcapsules (MAMCs) for controlled drug-delivery, wherein the MAMCs release one or more active ingredients in response to mechanical stimuli in a subject's body. The MAMCs provide a platform for stimulating biological regeneration, biological repair, modifying disease, and / or controlling disease in mechanically-loaded musculoskeletal tissues.

The invention discloses a drug targeted delivery device and method, and belongs to the technical field of intelligent medical treatment. The device comprises the following modules: an intelligent targeted recognition module for accurately recognizing a gastric cancer specific molecular marker and improving the selectivity and specificity of targeted recognition in combination with a dynamic surface modification strategy; the microenvironment real-time monitoring module is used for monitoring key physiological parameters of the gastric cancer microenvironment in real time; the intelligent path planning module is used for dynamically calculating and optimizing a drug delivery path and realizing accurate drug positioning; the personalized drug administration regulation and control module is used for accurately predicting the drug dosage demand of an individual and dynamically and finely adjusting the drug administration amount in real time; the drug resistance risk management module is used for early warning a drug resistance risk in advance and automatically generating a personalized alternative drug administration strategy through multi-dimensional drug resistance analysis and real-time early warning; and the intelligent drug release module adopts a temperature-sensitive / pH-sensitive polymer shell layer and a nano valve to control drug release, so that precise gradient release of drug concentration is realized.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to a 2-aminopyrimidine compound, application thereof and an antitumor drug. The 2-aminopyrimidine compound provided by the invention has a structure as shown in a formula (I). According to the invention, 2-aminopyrimidine is used as a mother nucleus structure, and a series of 2-aminopyrimidine compounds are successfully constructed by accurately introducing a biologically active imidazole, thiazole or oxazole nitrogen-containing heterocyclic ring fragment at the 5 # site of 2-aminopyrimidine; systematic in-vitro anti-tumor activity evaluation proves that the 2-aminopyrimidine compound with the structure as shown in the formula (I) provided by the invention shows remarkable inhibitory activity on various tumor cell lines, and the activity of part of the compound is even superior to that of a clinical control drug. The structural diversity of 2-aminopyrimidine compounds is enriched, valuable lead compounds are provided for developing novel efficient antitumor drugs, and the 2-aminopyrimidine compounds have important scientific significance and clinical transformation potential. # imgabs0 #

The invention belongs to the technical field of nano-medicines and targeted therapy, and particularly relates to a targeted nano-system nano-drug delivery system based on mesoporous polydopamine as well as a preparation method and application thereof, in particular to an N2E4-MPDA-Gem nano-system based on mesoporous polydopamine (MPDA). A targeting nano system based on mesoporous polydopamine comprises mesoporous polydopamine nano particles loaded with pancreatic cancer chemotherapy drugs, targeting molecules N2E4 are combined with the surfaces of the mesoporous polydopamine nano particles, and phenylboronic acid coatings used for controlling drug release are arranged on the surfaces of the mesoporous polydopamine nano particles. The system adopts a modular design, can be compatible with various chemotherapeutic drugs such as oxaliplatin, irinotecan and the like, and can be flexibly coupled with different targeting antibodies such as EGFR (epidermal growth factor receptor), HER2 (human epidermal growth factor receptor) and the like. A standard preparation process and good stability provide reliable guarantee for clinical transformation, and the compound shows an excellent treatment effect in a solid tumor model represented by pancreatic cancer.

The invention discloses a cognitive state monitoring and intervention device and method. The cognitive state monitoring and intervention device comprises a microelectrode drug delivery array module, a wireless transceiving and control circuit module and a power supply module, a microcontroller is embedded in the wireless transceiving and control circuit module; the microelectrode drug delivery array module comprises a hollow drug delivery microneedle, a sensing electrode and a controlled drug delivery electrode; the hollow drug delivery microneedle comprises a hollow microneedle array and a drug storage chamber; the sensing electrode is coupled and fixed on a substrate of the hollow microneedle array, and is attached to the body surface to monitor skin impedance signals when in use, liquid medicine is stored in the medicine storage chamber, and a controlled administration electrode is mounted in the medicine storage chamber; when the wireless transceiving and control circuit module applies current to the controlled dosing electrode, the controlled dosing electrode and the liquid medicine generate electrochemical reaction, and the liquid medicine is pumped into the body surface through the microneedle. According to the invention, the cognitive function state of the body can be continuously monitored, and accurate administration can be automatically realized.

The invention relates to the technical field of biology, in particular to silymarin inclusion compound lipidosome and a preparation method and application thereof. The silymarin inclusion compound liposome is prepared from the following components in parts by weight: 10 to 48 parts of silymarin, 10 to 53 parts of phospholipid, 5 to 10 parts of Arabic gum and 25 to 70 parts of cyclodextrin. According to the invention, cyclodextrin and phospholipid are combined to form a double-drug-loading structure; on the basis, Arabic gum is used as a film-forming agent to form a protective film on the surface of the liposome, so that the stability of the system is further improved; the silymarin inclusion compound is encapsulated in a water phase in the liposome, and meanwhile, part of free silymarin is encapsulated in a lipid bilayer. According to the structure, the solubility and the encapsulation efficiency of the silymarin are remarkably improved, the liposome stability is enhanced, the drug release is effectively controlled, and the silymarin inclusion compound lipid is simple in preparation process and suitable for industrial production.

The invention discloses a formula and a preparation process of a synthetic biotechnology-based endowed netting loss-control pesticide fertilizer, and relates to the technical field of fertilizers, the loss-control pesticide fertilizer is prepared from the following components by weight: 60-80 parts of a compound fertilizer, 10-20 parts of diammonium phosphate, 2-10 parts of trace elements, 2-8 parts of modified attapulgite, 1-4 parts of an insecticide, 0.5-3 parts of polyglutamic acid, and 1-5 parts of polyvinyl alcohol; according to the invention, a high-efficiency netting loss control system is formed through the energization of polyglutamic acid and the synergistic effect of multiple components, so that not only are the problems of easy nutrient loss and poor pesticide stability in the traditional pesticide fertilizer solved, but also the synergistic slow release of nutrients and pesticide is realized, the utilization rate of the fertilizer is remarkably increased, the control period of the pesticide is remarkably prolonged, and the application value is good.

The invention relates to preparation of 10-trifluoromethoxy camptothecin compounds and application of the 10-trifluoromethoxy camptothecin compounds in antitumor drugs. The structural formula of the compounds is shown in the specification. In-vitro cytotoxic activity screening results show that the 10-trifluoromethoxy camptothecin compound has broad-spectrum anti-tumor activity, and shows relatively strong inhibitory activity on human liver cancer cells (HepG2), human non-small cell lung cancer cells (A549), human colon cancer cells (SW480), human bile duct cancer cells (QBC939), human breast cancer cells (MCF-7), human pancreatic cancer cells (PANC-1) and human pancreatic cancer cells (BxPC-3). The compound 10-trifluoromethoxy camptothecin I and the compound 7-ethyl-10-trifluoromethoxy camptothecin II have a relatively strong inhibition effect on the detected seven tumor cell lines, and the IC50 (half maximal inhibitory concentration) values of the compound 10-trifluoromethoxy camptothecin I and the compound 7-ethyl-10-trifluoromethoxy camptothecin II are respectively 0.913 to 0.0661 mu M and 4.932 to 0.0578 mu M, which are obviously superior to those of a contrast drug topotecan. Wherein the compound I and the compound II show the strongest inhibitory activity on a BxPC-3 cell line, and the IC50 values of the compound I and the compound II are 0.0661 + / -0.0065 [mu] M and 0.0578 + / -0.0043 [mu] M respectively. Therefore, the 10-trifluoromethoxy camptothecin compound is expected to be developed into a novel antitumor drug. # imgabs0 #

The invention discloses a self-driven diagnosis and treatment integrated microneedle array paper-based chip as well as a preparation method and application thereof, and belongs to the technical field of biomedicine. The microneedle array chip system comprises a function integration module which at least comprises a self-powered extraction unit, a sensing detection unit and a controlled drug delivery unit. According to the microneedle array paper-based chip, biomarkers in skin interstitial fluid are efficiently collected based on a self-powered thermoelectric chemical battery microneedle, PtPB (at) PEG (at) HA nanoparticles loaded on an immunochromatography test strip combination pad are triggered to be subjected to ring opening, a hybridization chain reaction is induced to generate DNA nano-enzyme, and TMB is catalyzed to develop color; the open-loop nanoparticles can be used for SERS cross detection of biomarkers, and can be used as a thermal initiator to activate the phase change microneedle under the irradiation of near-infrared light, so that drugs are released as required, and precise treatment is realized. Besides, objective quantitative analysis of color signals is realized by constructing a convolutional neural network model, and the system has the functions of naked eye screening, intelligent quantification and personalized treatment, and can improve the home management ability of early skin cancer.

The invention discloses an exosome engineered targeted drug delivery system and a preparation method and application thereof, and belongs to the field of biomedices.The exosome engineered targeted drug delivery system is prepared by mixing and reacting surface modified exosome and pH response type drug controlled release nanoparticles; the pH response type drug controlled release nanoparticles react with the surface modified exosome through a click chemical reaction; the surface of the membrane of which the surface is modified with the exosome is modified with a maleimide group and an azide group; the novel nano-drug has pH responsiveness; the click chemical reaction is thiol-ene click reaction. Bifunctional groups (MAL and N3) are directionally grafted on the surface of an exosome membrane, uniform drug particles are prepared in combination with a micro-fluidic technology, an efficient bimodal targeting drug delivery system is successfully constructed, and remarkable technical advantages are shown in the aspects of improving targeting precision, enhancing antitumor activity, controlling drug release, inhibiting tumor metastasis and the like; and a new technical approach is provided for precise treatment of adenoid cystic carcinoma.

The present invention discloses a light-responsive Pickering emulsion that is synergistically stabilized by a spiropyran ionic liquid and UiO-66-NH2. The Pickering emulsion comprises an oil-water phase, and its stabilizer is a spiropyran ionic liquid and a metal-organic framework material UiO-66-NH2. The stable Pickering emulsion can undergo demulsification under additional visible light irradiation. When further irradiated with ultraviolet light, the system can be re-emulsified to form a stable Pickering emulsion. The Pickering emulsion provided by the present invention can be used for the Click reaction of hydrophilic azide compounds and terminal alkynyl compounds. Through reversible visible light and ultraviolet light regulation, the catalyst and spiropyran ionic liquid can be recycled, and the Pickering emulsion has application value in the fields of controlled drug release and sustainable catalysis.

The invention discloses a drug controlled release layer-by-layer self-assembly nano hydrogel boron carrying agent and application thereof, and belongs to the technical field of biomedicine. According to the method, calcium alginate nano-particles, calcium alginate nano-particles modified by polyallylamine hydrochloride, calcium alginate nano-particles modified by boric acid and polyallylamine hydrochloride, and calcium alginate nano-particles modified by polyallylamine hydrochloride, boric acid and polyallylamine hydrochloride are prepared in sequence. According to the invention, boric acid is loaded into the layer-by-layer self-assembled nano hydrogel material, so that intelligent controlled release can be realized, and the material is applied to boron neutron capture therapy. The material has good water solubility, good dispersity in an aqueous solution, small size and uniform particle size. The material also has good biocompatibility, intelligent and accurate release control is realized, and important technical progress is brought to cancer treatment.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

The invention relates to the technical field of drug delivery, and mainly relates to a water-in-water-in-water emulsion for drug delivery and a preparation method and application thereof. The preparation method comprises the following steps: preparing an anionic polysaccharide aqueous solution, and dissolving a medicine in the anionic polysaccharide aqueous solution to obtain a mixed solution; preparing a cationic polysaccharide aqueous solution or a protein aqueous solution; and adding the mixed solution into a cationic polysaccharide aqueous solution or a protein aqueous solution, mixing, and emulsifying to obtain the water-in-water-in-water emulsion for drug delivery. The water-in-water-in-water emulsion with high stability and excellent biocompatibility is successfully prepared through the synergistic effect of the cationic polysaccharide or the protein and the anionic polysaccharide without any emulsifier, and the unique particle structure of the emulsion is combined with a charge conversion mechanism to regulate and control drugs, realize slow release and prolong the drug effect time.